Drugs / SCH 486757
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00506987 | Jan → Nov 2007 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT00230230 | Oct 2005 → Apr 2007 | — | Merck Sharp & Dohme LLC | Completed | Missed primary |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SCH486757 | “Therefore, we compared the effect of NOP1 receptor agonist SCH486757 with matched placebo and codeine in a multicentre, double-blind, parallel-group study in patients with...” PMID 19937046 ↗ Jan 2010 |
| Action | Activate | “NOP1 receptor agonist SCH486757” PMID 19937046 ↗ Jan 20101“Nociceptin receptor agonist” CHEMBL4297427 ↗ |
| Modality | Small molecule | — CHEMBL4297427 ↗ |
| Route | Oral | “SCH 486757 2 x 50-mg capsule twice daily orally for 2 weeks” NCT00506987 ↗ |
| Target | OPRL1 | “Nociceptin receptor agonist” CHEMBL4297427 ↗ |